Study #2014-0756
An Open Label, Multicentre, Phase Ib/II Study of BGB324 Administered as a Single Agent or in Combination with Cytarabine or Decitabine in Patients with Acute Myeloid Leukemia or as a Single Agent in Patients with Myelodysplastic Syndrome
Study Status
Open
Treatment Agent
ARA-C,BGB324
Principal Investigator
Jorge Cortes
Description
The goal of this research study is to find the highest tolerable dose of BGB324 that can be given to patients with AML. Another goal of this study is to learn if the highest tolerable dose can help to control AML.
General Information
Disease Group: Leukemia
Treatment Agent: ARA-C,BGB324
Treatment Location: Both at MDACC & and Other Sites
Sponsor: BerGenBio, AS
Study Status
IRB Review and Approval Date: 02/26/2015
Recruitment Status: Open
Projected Accrual: 90
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia
Study phase:
Phase I
Physician name:
Jorge Cortes
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789